← Leaderboards
Wei Yang
Cedars-Sinai Medical Center
$2,107,820
Attributed
$3,459,034
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $507K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,459,034 · 2
By mechanism
R01$3,459,034 · 2
Top collaborators
- Dolores Di Vizio5 shared
- Andries Zijlstra3 shared
- Paula Jill Hurley2 shared
Most similar at Cedars-Sinai Medical Center
Same institution · by research overlap
- Neil A Bhowmick$9,206,432
- Mitchell Kronenberg$46,508,740
- Shelly Chi-Loo Lu$32,634,847
- Isla Pearl Garraway$1,077,887
- Gislaine A Martins$6,433,771
Others in their field
Other Emerging Leaders on “Clinic”
- Leonard Freedman · Leidos Biomedical Research, Inc.$978,089,882
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$321,499,704
- Lynn Briscoe · Leidos Biomedical Research, Inc.$317,501,839
Research focus
ClinicMolecularPreventCancer TypeMalignant Neoplasm Of ProstateCause Of DeathMalignant NeoplasmsMultidisciplinaryProstate Cancer CellProstate Cancer Cell LineCancer PatientBiomarker PanelBenignBiopsyBiomarker IdentificationBenchmarkingClinically SignificantClinical PredictorsCandidate MarkerCategoriesCancer PrognosisBiomarker DevelopmentBiomarker DiscoveryBiology
Grant awards (9)
RIPK2/MKK7/c-Myc Signaling as a Therapeutic Target in Prostate Cancer Metastasis$463,166
R01 · FY2025 · CA · contact PI
RIPK2/MKK7/c-Myc Signaling as a Therapeutic Target in Prostate Cancer Metastasis$486,109
R01 · FY2023 · CA · contact PI
RIPK2/MKK7/c-Myc Signaling as a Therapeutic Target in Prostate Cancer Metastasis$12,467
R01 · FY2023 · CA · contact PI
RIPK2/MKK7/c-Myc Signaling as a Therapeutic Target in Prostate Cancer Metastasis$470,471
R01 · FY2022 · CA · contact PI
High-throughput palmitoyl-proteomics profiling of extracellular vesicles for identification of biomarkers for early detection of clinically significant prostate cancer$325,459
R01 · FY2021 · CA
High-throughput palmitoyl-proteomics profiling of extracellular vesicles for identification of biomarkers for early detection of clinically significant prostate cancer$347,533
R01 · FY2020 · CA
High-throughput palmitoyl-proteomics profiling of extracellular vesicles for identification of biomarkers for early detection of clinically significant prostate cancer$507,028
R01 · FY2019 · CA
High-throughput palmitoyl-proteomics profiling of extracellular vesicles for identification of biomarkers for early detection of clinically significant prostate cancer$384,283
R01 · FY2018 · CA
High-throughput palmitoyl-proteomics profiling of extracellular vesicles for identification of biomarkers for early detection of clinically significant prostate cancer$462,518
R01 · FY2017 · CA